EUVIMEDEUVIMED entdecken
Crossref

Fraction metabolized by cytochrome P450 enzymes: A comprehensive evaluation of the translatability of an in vitro HepatoPac assay

Florian Klammers, Thanusa Shanmugalingam, Tobias Remus, Alexander Schriewer, Isabelle Walter, Neil Parrott, Kenichi Umehara

Drug Metabolism and Disposition · 2026

DOI: 10.1016/j.dmd.2025.100223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026. Verfasst von Florian Klammers und 6 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland. Hauptthemen laut MEDLINE: Hepatocytes, Cytochrome P-450 Enzyme System. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: F. Hoffmann-La Roche, Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In our previous study, long-term cocultured hepatocytes were used to estimate the fraction of a drug metabolized by CYP3A4 (fm,CYP3A4). Metabolic turnover was measured with and without a CYP3A4 selective inhibitor, and the results were verified against in vivo reference data. The current study followed a similar approach using direct or time-dependent inhibitors to evaluate fm,CYP1A2, fm,CYP2C8, fm,CYP2C9, fm,CYP2C19, and fm,CYP2D6 for a set of marketed drugs. The used inhibitors were for CYP1A2 (20 μM furafylline), CYP2C8 (40 μM montelukast), CYP2C9 (40 μM sulfaphenazole), CYP2C19 (3 μM (-)N-3-benzyl-phenobarbital), and CYP2D6 (5 μM quinidine). We found that in vitro fm values above 0.5 were comparable to in vivo values, falling within a 0.5 to 2-fold error in 9 of 11 CYP1A2 substrates, 5 of 8 CYP2C8 substrates, 5 of 8 CYP2C9 substrates, 2 of 3 CYP2C19 substrates, and 11 of 20 CYP2D6 substrates. The study also showed how uncertainty in measured metabolic turnover affects the estimated fm,CYPs, revealing that when estimated fm errors are

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepatocytesCytochrome P-450 Enzyme SystemHumansCytochrome P-450 Enzyme InhibitorsCoculture TechniquesCells, CulturedPharmaceutical PreparationsMicrosomes, Liver

Stichwörter der Autor:innen

Drug-drug interactionFraction metabolizedHepatoPacLong-term co-cultured hepatocytesPrediction

Substanzen

Cytochrome P-450 Enzyme SystemCytochrome P-450 Enzyme InhibitorsPharmaceutical Preparations

Autor:innen und Institutionen

  • Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland.
  • Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland. Electronic address: kenichi.umehara@roche.com.

Förderung

  • F. Hoffmann-La Roche
  • Roche

Zitieren

APA

Klammers, F., Shanmugalingam, T., Remus, T., Schriewer, A., Walter, I., Parrott, N., & Umehara, K. (2026). Fraction metabolized by cytochrome P450 enzymes: A comprehensive evaluation of the translatability of an in vitro HepatoPac assay. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100223

Vancouver

Klammers F, Shanmugalingam T, Remus T, Schriewer A, Walter I, Parrott N, et al. Fraction metabolized by cytochrome P450 enzymes: A comprehensive evaluation of the translatability of an in vitro HepatoPac assay. Drug Metabolism and Disposition. 2026. doi:10.1016/j.dmd.2025.100223

BibTeX
@article{Klammers2026,
  author = {Klammers, Florian and Shanmugalingam, Thanusa and Remus, Tobias and Schriewer, Alexander and Walter, Isabelle and Parrott, Neil and Umehara, Kenichi},
  title = {Fraction metabolized by cytochrome P450 enzymes: A comprehensive evaluation of the translatability of an in vitro HepatoPac assay},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  doi = {10.1016/j.dmd.2025.100223}
}
Kostenlos starten →